Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy

Stopped Study was prematurely terminated at the time of the first Interim Analysis (IA) as the study did not meet its primary efficacy objective.

Conditions

• Patient Diagnosed With OCD and Resistant to SSRI Treatment
• Failed SSRI Over 12 Weeks at Appropriate Doses

Interventions

• DRUG: AFQ056
• DRUG: Placebo

Sponsor

Novartis Pharmaceuticals